Background: Inflammatory bowel diseases (IBD) are associated with altered bone health and increased risk for fractures. Vitamin D deficiency is
I
nflammatory bowel diseases (IBD) are chronic relapsing disorders associated with altered bone health, [1] [2] [3] [4] [5] [6] [7] [8] increased risk for bone fractures, [9] [10] [11] [12] and, probably, impaired muscle function. 6, 7 The possible risk factors associated with bone fragility include disease activity, prolonged treatment with corticosteroids, malabsorption, vitamin D deficiency, impaired muscle function, compromised linear growth, and delayed puberty. 13 Vitamin D is an important factor for bone health. 14 Vitamin D deficiency seems to be highly prevalent among pediatric patients with IBD, 15, 16 and some (but not all 17 ) studies have shown that patients with IBD present with lower 25-hydroxyvitamin D (25OHD) serum levels compared with those observed in the healthy population. 18 Winter season, dark skin, involvement of the upper gastrointestinal tract (in Crohn's disease [CD] ), more severe disease course, low serum albumin level, low body mass index, and low weight Z-score were identified as risk factors for lower 25OHD in pediatric patients with IBD. 15, 16, 19, 20 In contrast to adults, 21 25OHD levels were not correlated with bone mineral content in cross-sectional studies in children with IBD. 2, 15 Although different administration regimes of vitamin D have been tested in pediatric patients with IBD, [22] [23] [24] the appropriate mode and dosage of supplementation is unclear. Based on a recent randomized controlled trial, 24 daily oral administration of 2000 IU of cholecalciferol seems to be safe; however, it is still challenging to achieve a 25OHD concentration above 80 nmol/L during the whole year, which was the primary endpoint of this study.
The rationale for cholecalciferol supplementation in chronic diseases is based on the established effect of vitamin D on bone mineralization mediated by calcium absorption from the gut. Little is known about the effect of vitamin D on skeletal muscles; however, animal studies have shown its positive role in the regulation of myogenesis. 25 Owing to the insufficient data, a recent meta-analysis of randomized controlled trials (RCTs) on the efficacy of vitamin D supplementation on bone mineral density (BMD) in patients with IBD failed to reach a conclusion. 26 A pediatric study by Benchimol et al 27 failed to show a difference in the improvement of BMD between patients treated with 50,000 IU of 25OHD once per month and patients supplemented with calcium alone. Although some RCTs showed a positive effect of vitamin D supplementation on bone quality in healthy children, [28] [29] [30] [31] other studies failed to find a significant impact on BMD. 32, 33 Similarly, the impact of vitamin D supplementation on muscle function is still unclear. While a study showed that parenteral vitamin D supplementation did not significantly improve muscle function in healthy adolescent girls, 34 another recent association study showed significantly higher muscle strength in boys with serum levels of 25OHD in the highest tertile compared with those with serum levels of 25OHD in the lowest tertile. 35 
Primary and Secondary Aims
The primary aim of our study was to observe the changes in bone quality parameters measured by peripheral quantitative computed tomography (pQCT) and dynamic muscle functions assessed by jumping mechanography after daily substitution of 2000 IU of cholecalciferol for 12 months in a cohort of pediatric patients with IBD. Secondarily, we assessed the changes in 25OHD serum levels and tried to find potential predictors (baseline values of bone and muscle characteristics, anthropometric parameters, and 25OHD levels) to determine patients suitable for vitamin D substitution.
MATERIALS AND METHODS

Design and Subjects
The study was designed as a longitudinal prospective observational study. Between 2011 and 2013, we screened all pediatric patients with IBD followed at our tertiary referral center, for eligibility ( Fig. 1) to enter this study. Patients aged between 5 and 19 years, those who were diagnosed with IBD based on Porto criteria 36, 37 and those who showed a willingness to participate in the study were included. Patients who had other disease that has a known impact on the muscle-bone unit (patients with compensated autoimmune thyroiditis were not excluded), those who showed noncompliance to treatment, pregnant women, patients who had undergone extensive small bowel surgery, and those on total parenteral nutrition and growth hormone therapy were excluded. Among the 70 patients who were enrolled, 55 (79%) completed the study.
The blood sampling, bone density and strength assessment, and muscle function analyses were performed at the initiation (baseline visit) and then between 12 and 24 months (median 13.8 months, interquartile range 12.0-16.0) of vitamin D supplementation (last follow-up visit). Regular clinical follow-up of the patients was conducted between these visits, at intervals of 2 to 3 months. We had retrospectively collected the basic characteristics of the patients and applied the Montreal classification at the time of diagnosis. The cumulative dose of corticosteroids over 12 months before initiation of vitamin D supplementation was calculated and the percentage of patients treated with corticosteroids was noted. The information about treatment was collected at every visit.
Vitamin D Supplementation
No patient received any regular substitution of vitamin D or calcium at the screening visit. Enteral nutrition was not considered as supplementation. Three months after the screening visit, all patients were prescribed 2000 IU of cholecalciferol (oral drops) (Vigantol; Merck KGaA, Darmstadt, Germany) daily. The levels of 25OHD were tested every 2 to 3 months, during the regular follow-up.
Disease Activity and Laboratory Parameters
We obtained blood samples and assessed disease activity on the day of the muscle and bone assessment (baseline and last follow-up) and during interim outpatient clinic visits. Activity of the disease was assessed using the pediatric ulcerative colitis activity index (PUCAI) in patients with ulcerative colitis (UC) and using pediatric Crohn's disease activity index (PCDAI) in combination with C-reactive protein in patients with Crohn's disease (CD). The remission was defined as pediatric ulcerative colitis activity index ,10 points in patients with UC and pediatric Crohn's disease activity index ,10 points in combination with C-reactive protein ,5 mg/L in patients with CD. Simultaneously, we tested the erythrocyte sedimentation rate, the levels of serum albumin, parathormone (electrochemiluminescence immunoassay), serum calcium, and full blood count. The levels of 25OHD were determined using chemiluminescent microparticle immunoassay.
Anthropometry
The body height was measured to the nearest 1 mm, using the anthropometer A-226 (Trystom, Olomouc, Czech Republic). Body weight was measured to the nearest 0.1 kg (with the patients wearing just their underwear), using an electronic scale (TH200; Tonava, Upice, Czech Republic). The body mass index was calculated using the formula: body weight (kg)/body height 2 (m). Gender-and age-specific Z-scores were calculated using Czech national reference data. 38 
Dynamic Muscle Function Assessment
Dynamic muscle functions were assessed using jumping mechanography (Leonardo Mechanograph Ground Reaction Force Plate; Novotec Medical GmbH, Pforzheim, Germany), as described elsewhere. 39 The mechanograph consists of two symmetrical force plates, each equipped with eight force sensors. The force sensors record the vertical ground reaction force exerted on the platform at the frequency of 800 Hz. 40 The signal was analyzed using the software provided by the manufacturer (Leonardo Mechanography GRFP version 4.2). Single two-leg jumping and multiple one-leg hopping tests were used to assess the dynamic muscle functions. Maximal muscle power (P max , W) and maximal power adjusted for the body mass (P max /mass, W/kg) of the patients were assessed using the single two-legged jumping test. Maximal muscle force (F max , N) and maximal force adjusted for the body weight (F max /body weight, no unit) of the patients were assessed using the multiple one-leg hopping test. The tests were repeated three times and only the highest value recorded was selected for further analysis. Gender-and height-specific Z-scores were calculated using previously published reference data. 39 Body mass and body weight were calculated in the resting position before starting the test, using the integrated software.
Bone Strength Assessment
In this study, pQCT scanner XCT 2000 (Stratec Medizintechnik, Pforzheim, Germany) was used for bone analyses at the nondominant tibia. The length of the tibia was measured to the nearest 1 mm, from the medial malleolus to the superior margin of the medial condyle of the tibia. To determine the position of the distal tibial growth plate and to adjust the reference lines, a scout scan was performed, followed by two single scans with 0.4-mm voxel size and 2.0-mm slice thickness. These scans were performed at a distances corresponding to the 4% and 66% of the measured bone length. At the distal tibia (4% site), trabecular BMD was measured. At the proximal tibia (66% site), the cortical BMD and thickness, total and cortical bone cross-sectional area (total cross-sectional area (CSA), cortical CSA), and the polar Strength-Strain Index were measured. The images were analyzed and numerical values were calculated using the integrated XCT software, version 6.20 C. Only good-quality scans without movement artifacts were used for further analysis. Gender-and heightspecific Z-scores were calculated using the reference data published by Moyer-Mileur et al. 41 To insure the accuracy of measurement, the scanner was calibrated once a week using a phantom provided by the manufacturer.
Statistical Analysis
All data were analyzed using R statistical software (version 3.2.3). 42 Continuous variables were described as median and interquartile range. Categorical variables were described as absolute frequencies and percentages. The Z-scores were tested for difference from zero using the one sample t-test. A linear mixed model (R package "lme4" 43 and "lmerTest" 44 ) was used to test the effect of cholecalciferol substitution on 25OHD levels during the study period and on the anthropometric, mechanographic, and pQCT characteristics at the baseline and last visit. The selection of the variables included in the regression models was based on the Akaike information criterion, using automatic backward elimination of all effects of the linear mixed effects model. To test whether the changes of bone and muscle characteristics truly depend on cholecalciferol substitution, we constructed the linear mixed model where trabecular BMD, Strength-Strain Index, P max , P max /mass, F max , or F max /body weight Z-scores were the outcomes, and cholecalciferol substitution, the duration of cholecalciferol substitution, body weight, the diagnosis (CD or UC), disease activity (remission), age at baseline visit, the duration of disease treatment at baseline visit, the proportion of patients on corticosteroids during the last 12 months and, in the case when bone parameters were used as outcomes, the Z-scores of P max , P max /mass, F max , and F max /body weight and the other bone measure (Strength-Strain Index or trabecular BMD Z-scores) and, in case when muscle parameters were used as outcomes, the Z-scores of trabecular BMD and Strength-Strain Index were used as predictors.
To determine the predictors of improvement of trabecular BMD Z-score and P max /mass Z-score, we used linear regression modeling. The models testing each predictor (baseline outcome value, e.g., trabecular BMD Z-score at baseline or P max /mass Z-score at baseline, 25OHD levels at baseline, corticosteroids administered last year as categorical variables, and remission at baseline) were adjusted for age, sex, duration of substitution, and disease (CD versus UC). These predictors and covariables were selected according to the clinical consideration. P values less than 0.05 were considered statistically significant. All P values were two sided.
ETHICAL CONSIDERATIONS
The study was approved by the ethics committee of the hospital, and informed consent was obtained from the parents of all patients.
RESULTS
Baseline Patient Characteristics
Patient characteristics and Montreal classification 45 are summarized in Table 1 . Complete assessment of dynamic muscle functions by jumping mechanography could not be performed in only one patient because of her acute physical condition.
Changes in Anthropometric Characteristics
Our patients were slightly shorter and lighter than healthy subjects of the same age (P , 0.001 for both). Anthropometric parameters were not different between the baseline and last follow-up visit (Table 2) .
Changes in Laboratory Parameters
During the study period, 226 measurements of serum 25OHD levels from 55 patients were obtained. The median number of measurements per patient was 5 (range 4-6). We found an association between daily oral cholecalciferol substitution and 25OHD serum levels, using the linear mixed model (P , 0.001). Among all observations of 25OHD levels after substitution had commenced, 76% of the participants had 25OHD levels permanently .50 nmol/ L and 98% subjects had levels .30 nmol/L. The median serum 25OHD levels increased from 58 nmol/L at the baseline visit to 85 nmol/L at the last follow-up visit (Table 2 ). Figure 2 shows the percentage of patients with 25OHD levels above the defined cutoffs at the baseline and last follow-up visits, in paired observations.
Changes in Bone Quality
The Z-scores of trabecular BMD, cortical bone CSA, and cortical thickness were lower at the baseline compared with reference (P , 0.001, P ¼ 0.035, and P , 0.001, respectively), and they significantly improved at the last visit (P , 0.001, P , 0.001, and P , 0.001, respectively). Baseline Z-scores for total bone CSA and Strength-Strain Index did not differ from the reference and improved at the last visit (P ¼ 0.001 and 0.002, respectively). Only the cortical BMD Z-score was higher at the baseline (P , 0.001) and remained unchanged at the last visit (Table 2) .
Changes in Muscle Functions
Among all the tested baseline parameters, only P max Z-score was lower than that in healthy subjects (P ¼ 0.018). Although F max and F max /body weight Z-scores remained unchanged between the baseline and last visit, P max and P max / mass increased significantly (P , 0.001 and P ¼ 0.002, respectively; Table 2 ).
Predictors of Bone Quality
Using the described statistical methods, we constructed a model (Table 3) to determine the independent predictors of The medians and interquartile ranges are shown for continuous variables, whereas categorical variables are described by the absolute frequencies and percentages. CD, Crohn's disease; GI, gastrointestinal; UC, ulcerative colitis. The median prednisolone cumulative dose for these subjects was 3.9 (IQR 2.9-47.2) mg$kg 21 $y
21
. 25OHD, 25-hydroxycholecalciferol; BMD, bone mineral density; BMI, body mass index; CSA, cross-sectional area; PCDAI, pediatric Crohn disease activity index; PUCAI, pediatric ulcerative colitis activity index; TNF, tumor necrosis factor. bone health. Trabecular BMD Z-score was positively associated with cholecalciferol substitution (beta 0.26, 95% confidence interval [CI] 0.14-0.37, P , 0.0001); conversely, Strength-Strain Index Z-score was not significantly associated. The association between trabecular BMD Z-score and cholecalciferol substitution was independent of the serum levels of 25OHD (data not shown).
Predictors of Muscle Function
The models for predicting muscle characteristics are described in Table 4 . We found that P max and P max /mass Z-scores were associated with cholecalciferol substitution (beta 0.60, 95% CI 0.32-0.85, P , 0.0001 and beta 0.20, 95% CI 0.029-0.37, P ¼ 0.043, respectively). On the contrary, F max and F max /body weight Z-scores were not significantly associated with cholecalciferol substitution. The association between P max and P max /mass Z-scores, and cholecalciferol substitution was independent of serum levels of 25OHD (data not shown).
Prediction of Patients Who Would Benefit from Substitution
Trabecular BMD Z-scores improved in 40 (73%) patients and P max /mass Z-score improved in 37 (69%) patients. Only three out of the 55 patients (5%) failed to show improvements in trabecular BMD or P max /mass Z-scores. Hence, the possibility of determining the predictors for identification of these three patients was very low in our cohort. Therefore, we focused on the predictors that can identify the patients with the most profound changes in bone and muscle measures.
Among the tested baseline predictors (bone quality, muscle function and anthropometry parameters, and 25OHD levels), we found that only baseline Z-score of trabecular BMD was a negative predictor of changes in trabecular BMD Z-score in the model adjusted for sex, age, type of the disease (CD versus UC), and duration of cholecalciferol substitution (beta 20.10, 95% CI 20.19 to 20.01, P ¼ 0.031). Similarly, only low P max / mass Z-score at the baseline (beta 20.31, 95% CI 20.52 to 20.01, P ¼ 0.005) was negatively associated with changes in P max /mass Z-score at the last follow-up, in the adjusted model.
DISCUSSION
In this study, we found that daily oral administration of 2000 IU of cholecalciferol was associated with improvement in trabecular BMD at the tibia and muscle power in pediatric patients with IBD. On the contrary, other important muscle-bone unit parameters such as the Strength2Strain Index and maximum muscle force remained unchanged. The predictors were selected based on the Akaike information criterion, using automatic backward elimination of all effects of the linear mixed effects model. The age at baseline visit, the duration of disease treatment at baseline visit, the diagnosis (CD or UC), corticosteroid treatment within last 12 months, cholecalciferol substitution status (yes/no), the duration of cholecalciferol substitution, disease remission (defined as PUCAI ,10 points in UC patients and PCDAI ,10 points in combination with CRP , 5 mg/L in CD patients), muscle functions (P max , P max /mass, F max and F max /body weight Z-scores) and Strength-Strain Index and trabecular BMD Z-scores, respectively, were used as predictors in the initial multiple regression mix models (before the selection of explanatory variables was performed). BMD, bone mineral density; F max , maximal muscle force; F max /body weight, maximal muscle force adjusted for subject's body weight; P max , maximal muscle power; P max / mass, maximal muscle power adjusted for subject's body mass.
Baseline Bone and Muscle Measures
Baseline data showed that volumetric bone density and bone geometry at the tibia were negatively altered in patients with IBD, when compared with the healthy population. This finding is in agreement with previously published studies. 6, 7 On the contrary, mechanography parameters were comparable with those in healthy children at the baseline, with the exception of P max Zscore, which was decreased. During follow-up and vitamin D supplementation, we observed a significant positive change in both bone health parameters and P max in the majority of patients. In a study by Benchimol et al, 27 patients with lumbar spine area BMD ,21 were substituted with 50,000 IU of 25OHD monthly for 6 months in one arm and with 1000 mg of elemental calcium daily in the second arm. No significant difference was found between these two small groups or between these patients and those with normal BMD in the lumbar spine area at the baseline, without any intervention during follow-up. BMD was evaluated using dual-energy X-ray absorptiometry (DXA). In contrast to pQCT, dual-energy X-ray absorptiometry does not enable distinction between trabecular and cortical bone density, and is unable to assess bone geometry; thus, the changes that we observed with pQCT might be missed with dual-energy X-ray absorptiometry.
To the best of our knowledge, no studies have described the effect of cholecalciferol substitution on muscle function in pediatric patients with IBD thus far.
Improvement in Muscle-Bone Unit with Cholecalciferol Substitution
We did not prove any substantial effect of disease activity on the bone-muscle unit in our patients with IBD. In contrast, it has been shown that bone quality could improve in patients with IBD who receive standard therapy without any other intervention, especially in the first few months after manifestation, owing to decreased inflammation activity. 6, 7 In an inception cohort study, Dubner et al 6 showed an improvement of trabecular BMD during the first 6 months after diagnosis of IBD; however, no change was found during the second half of the first year of treatment. Similarly, in a cross-sectional study, patients assessed shortly after diagnosis had more impaired bone-muscle unit, compared with that in patients assessed longer after the diagnosis. 7 The discrepancy between our study and previous studies could be explained by the fact that the median follow-up period from diagnosis till the baseline in our cohort was 1.8 years (interquartile range 1-4 years), which was significantly longer than the follow-up period in previous studies. Thus, we assume that the observed changes in bone and muscle parameters in our patients were not caused by the initiation of IBD therapy, which can be further supported by the similar proportions of patients in remission at the baseline and last follow-up visits (56% versus 67%, respectively). Moreover, the median disease activity indices (pediatric Crohn's disease activity index or pediatric ulcerative colitis activity index) and the levels of C-reactive protein remained stable (Table 2) at both time points of assessment. Meanwhile, we cannot exclude the possibility that treatment of IBD induces changes in the muscle-bone unit that could be apparent later after diagnosis, when the disease itself is already under control.
Role of Steroids and Antitumor Necrosis Factor Treatment
Studies on the role of glucocorticoids in the bone health of children with IBD show conflicting results 6, 7, 46 ; however, some studies showed a negative effect of glucocorticoids on BMD. [47] [48] [49] [50] The models in our study did not identify corticotherapy as a negative predictive factor for bone and muscle parameters; however, prolonged treatment with corticosteroids was rarely provided to our patients. Among children who were treated using corticosteroids, the cumulative dose of prednisone was 29 mg$kg 21 $yr 21 (interquartile range 20-39 mg$kg 21 $yr 21 ). Moreover, these low doses were taken only by 25% of patients within 12 months before the baseline visit and by 9% of patients within 12 months before the second assessment. Our study was neither focused nor powered enough to show the influence of corticotherapy on the muscle-bone unit. Therefore, the study does not allow for definite conclusion about the impact of corticoid treatment history on the development of musculoskeletal measures.
Although recent studies have suggested a protective role of antitumor necrosis factor treatment in the bone health of patients The predictors were selected based on the Akaike information criterion, using automatic backward elimination of all effects of the linear mixed effects model. The age at baseline visit, the duration of disease treatment at baseline visit, the diagnosis (CD or UC), corticosteroid treatment within last 12 months, cholecalciferol substitution status (yes/no), the duration of cholecalciferol substitution, disease remission (defined as PUCAI ,10 points in UC patients and PCDAI ,10 points in combination with CRP ,5 mg/L in CD patients), trabecular BMD and Strength-Strain Index Z-scores were used as predictors in the initial multiple regression mix models (before the selection of explanatory variables was performed). BMD, bone mineral density; F max , maximal muscle force; F max /body weight, maximal muscle power adjusted for subject's body weight; P max , maximal muscle power; P max / mass, maximal muscle power adjusted for subject's body mass.
with IBD who do not receive vitamin D substitution, 51, 52 we did not find this modality to impact the effect of substitution. Moreover, antitumor necrosis factor treatment was not predictive in selecting patients suitable for supplementation (data not shown).
Improvement of Serum 25OHD Levels with Cholecalciferol Substitution
Baseline serum levels of 25OHD in our cohort were comparable with previously published pediatric data. 15, 53 A significant proportion of patients showed improved vitamin D status after cholecalciferol supplementation. Our approach to supplement with 2000 IU of cholecalciferol was safe, and we did not experience any laboratory or clinical signals of overdosing. The 25OHD serum level of 80 nmol/L, which has been suggested as an appropriate target level for children with IBD, 24 was achieved in more than one-half of our patients. Our study design does not allow us to discuss the vitamin D supplementation strategy in patients with IBD in general, but as the vast majority of our patients achieved vitamin D sufficiency 14 at the last visit and did not show increased parathyroid hormone levels, we cannot assume that an even higher dosage could result in a better biological action.
Prediction of Patients Who Would Benefit from Cholecalciferol Substitution
The finding of the current study that cholecalciferol substitution improves the muscle-bone unit in pediatric patients with IBD at least to some extent raises a question about the patients who are more likely to benefit from the supplementation. Although we found that low baseline Z-scores of trabecular BMD and P max /mass predicted improvement of the respective parameters, the associations were relatively weak, and we were unable to construct a sufficiently robust model to select patients suitable for supplementation. Importantly, we did not find baseline levels of 25OHD predictive for trabecular BMD or for P max /mass Z-scores improvement. Based on our findings, we conclude that serum 25OHD levels are not valid markers of sufficiency and, thus, could account for the previous observations showing no relation between vitamin D status, and bone density 2, 15 and muscle CSA in children with IBD. 7 Only 5% of patients showed no improvement in trabecular BMD or P max /mass Z-score; thus, it is clinically irrelevant to identify predictors for selecting these 5% of patients. Until better predictors are found, cholecalciferol substitution seems to be reasonable for all pediatric patients with IBD.
Clinical Relevance of Data
Although previously published studies show that decreased volumetric bone density is associated with an increased risk for fracture in healthy children, 54 owing to insufficient data, we cannot conclude whether improvement in bone and muscle measures due to vitamin D substitution actually decreases the risk for fractures in pediatric population with IBD. Moreover, inconsistent data exist on differences in fracture prevalence between healthy children and children with IBD. 11, 12 Further, the need for screening of asymptomatic vertebral fractures has been discussed. 10, 55 To clearly answer this question, a placebocontrolled randomized controlled trial assessing the influence of vitamin D substitution on the frequency of fractures during several years of follow-up in patients with IBD is required.
Limitations of the Study
The study had some limitations. First, it was not an interventional study and no control population was recruited. This was due to insufficient number of patients to be randomly distributed into treatment or placebo intervention groups. Moreover, relatively substantial amount of missing values, mainly of 25OHD serum levels, affected the reliability of the conclusion with regard to the secondary outcome. In particular, we decided to use repetitive measures of 25OHD from individual patients to test the association between cholecalciferol substitution and the change in 25OHD serum levels. However, we have adjusted for the random effect of individual patients by using the mixed model, to overcome the potential impact of unequal number of repetitive measurements.
Although the variation in the follow-up period between baseline and the last visit was not a significant predictor in the regression mixed model and did not influence the significance of the other predictors of trabecular BMD Z-score in the regression model, this could also be considered as a limitation. Nevertheless, after creating an arbitrary threshold at 18 months of follow-up to divide the study participants into two groups (i.e., follow up , 
CONCLUSION
In conclusion, we demonstrated the association between daily supplementation with 2000 IU of oral cholecalciferol, and improvement in trabecular BMD and maximal muscle power in children with IBD. Substitution of 2000 IU of cholecalciferol helped the vast majority of our patients to achieve vitamin D sufficiency, and was safe. Although we were unable to find a sufficiently strong predictor for identifying patients suitable for substitution, and despite the observational design of our study and the short-term follow-up, we conclude that it seems reasonable to consider vitamin D substitution in all pediatric patients with IBD.
